Jubilant Life Sciences’ arm enters into exclusive out-licensing agreement with Checkpoint

27 May 2016 Evaluate

Jubilant Life Sciences’ subsidiary and Checkpoint Therapeutics, Inc. (Checkpoint), a subsidiary of Fortress Biotech, Inc. have inked an exclusive, worldwide license agreement under which Jubilant Biosys will out-license to Checkpoint a family of patents covering compounds that inhibit BRD4, a member of the BET (Bromodomain and Extra Terminal) domain for cancer treatment. The deal includes an upfront payment of $2 million and contingent preclinical, clinical and regulatory payments including commercial milestones totaling up to $180 million.

Jubilant Biosys will also receive research funding and royalty payments on successful commercialization of the compounds. Checkpoint will assume all further preclinical, clinical development and commercialization responsibilities.

Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.



Jubilant Pharmova Share Price

1074.30 7.05 (0.66%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×